Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma

Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma

Background: Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) is a personalized immunotherapy. The efficacy of TIL-ACT has been demonstrated prospectively in patients with advanced melanoma but is not limited to melanoma patients. Many patients are refractory to TIL-ACT, however,...

Full description

Saved in:
Bibliographic Details
Main Authors: D. König, B. Kasenda, M. Sandholzer, A. Chirindel, A. Zingg, R. Ritschard, H. Thut, K. Glatz, E.A. Kappos, D. Schaefer, C. Kettelhack, J. Passweg, K. Baur, A. Holbro, A. Buser, D. Lardinois, L.T. Jeker, N. Khanna, F. Stenner, M.S. Matter, N. Rodrigues Mantuano, M. Binder, A. Zippelius, H. Läubli
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Immuno-Oncology and Technology
Subjects:
melanoma
adoptive cell therapy
tumor-infiltrating lymphocytes
nivolumab
phase I trial
Online Access:http://www.sciencedirect.com/science/article/pii/S259001882400025X
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S259001882400025X

Similar Items